This geneticist’s age-reversal tech could help restore sight

Yuancheng (Ryan) Lu, a 34-year-old geneticist, is motivated by both his family history and personal risk factors to study age-related vision loss. His great-aunt in China died after being unable to see oncoming traffic, and Lu himself carries a genetic mutation linked to macular degeneration, a leading cause of blindness in older adults. Sunlight exposure is another risk factor for this condition, which is why he wears darkening aviator glasses that adjust to brightness automatically. Lu works at the Whitehead Institute in Cambridge, Massachusetts, where he focuses on developing gene therapies to prevent or reverse age-related vision loss. His personal connection to the issue drives his scientific research, which aims to address a critical health concern with potential life-changing implications.

In 2018, while completing his PhD at Harvard Medical School, Lu achieved a significant breakthrough in rejuvenation science by using reprogramming to repair damaged optic nerves in mice. Reprogramming is a technique that involves resetting the biological age of cells by introducing specific genes. Lu crushed the optic nerves of the mice to induce blindness, then injected the cells with a gene therapy containing three key genes (OSK), omitting a fourth gene (Myc) to reduce the risk of harmful effects like cancer. Sixteen days later, the mice’s optic nerves began regenerating, with visible growth observed under a microscope. Further tests in a rotating light box confirmed that the mice had regained their vision. This experiment demonstrated that age-related damage to nerves could be reversed, offering hope for treating human conditions like glaucoma and macular degeneration.

The gene therapy developed by Lu for mice, now called ER-100, has entered human clinical trials. On June 9, 2026, Life Biosciences—a startup cofounded by Lu’s former mentor, longevity scientist David Sinclair—announced that the first human had received the treatment for glaucoma. The trial has generated significant media attention, with headlines suggesting that the technology could change humanity. The treatment is nearly identical to the version Lu created as a student, highlighting the rapid transition from lab research to real-world application. While Sinclair has suggested that humans might one day live to 200 years old, Lu remains skeptical, emphasizing that aging involves multiple complex processes that cannot be addressed by a single solution.

Reprogramming is a biological process inspired by how embryos reset the age of cells to a youthful state before birth. In 2006, Japanese researchers discovered that introducing four specific genes (OSKM) into an old cell could turn it into a stem cell, effectively rejuvenating it. However, this process carries risks, particularly the gene Myc, which can cause uncontrolled cell growth or cancer. Lu refined the technique by removing Myc, using only the genes OSK, and applying it to the optic nerve—a part of the body that is relatively accessible for treatment. This adaptation made the therapy safer while still demonstrating its potential to reverse age-related damage in nerve cells.

Lu’s 2020 publication in the journal Nature sparked a surge of investment in anti-aging research, with US tech billionaires funding private companies like Altos Labs and NewLimit. On the day Lu was interviewed, he had met with Zhong Shanshan, one of China’s wealthiest individuals, to discuss potential collaborations. Despite the growing hype around age-reversal technologies, Lu has remained focused on his lab work, aiming to develop the next generation of rejuvenation therapies. He acknowledges that while reprogramming proved that molecular age can be reversed, it is not a universal solution. For example, he recently identified a gene that protects the retina from damage caused by free radicals, which are unstable molecules linked to age-related macular degeneration. Lu emphasizes that aging involves many factors, and no single therapy will address all of them.